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Abstract
Introduction The optimal dialysis dose for the treatment of
acute kidney injury (AKI) is controversial. We sought to evaluate
the relationship between renal replacement therapy (RRT) dose
and outcome.
Methods We performed a prospective multicentre
observational study in 30 intensive care units (ICUs) in eight
countries from June 2005 to December 2007. Delivered RRT
dose was calculated in patients treated exclusively with either
continuous RRT (CRRT) or intermittent RRT (IRRT) during their
ICU stay. Dose was categorised into more-intensive (CRRT ≥
35 ml/kg/hour, IRRT ≥ 6 sessions/week) or less-intensive
(CRRT < 35 ml/kg/hour, IRRT < 6 sessions/week). The main
outcome measures were ICU mortality, ICU length of stay and
duration of mechanical ventilation.
Results Of 15,200 critically ill patients admitted during the
study period, 553 AKI patients were treated with RRT, including
338 who received CRRT only and 87 who received IRRT only.
For CRRT, the median delivered dose was 27.1 ml/kg/hour
(interquartile range (IQR) = 22.1 to 33.9). For IRRT, the median
dose was 7 sessions/week (IQR = 5 to 7). Only 22% of CRRT
patients and 64% of IRRT patients received a more-intensive
dose. Crude ICU mortality among CRRT patients were 60.8%
vs. 52.5% (more-intensive vs. less-intensive groups,
respectively). In IRRT, this was 23.6 vs. 19.4%, respectively. On
multivariable analysis, there was no significant association
between RRT dose and ICU mortality (Odds ratio (OR) more-
intensive vs. less-intensive: CRRT OR = 1.21, 95% confidence
interval (CI) = 0.66 to 2.21; IRRT OR = 1.50, 95% CI = 0.48 to
4.67). Among survivors, shorter ICU stay and duration of
mechanical ventilation were observed in the more-intensive RRT
groups (more-intensive vs. less-intensive for all: CRRT (median):
15 (IQR = 8 to 26) vs. 19.5 (IQR = 12 to 33.5) ICU days, P =
0.063; 7 (IQR = 4 to 17) vs. 14 (IQR = 5 to 24) ventilation days,
P = 0.031; IRRT: 8 (IQR = 5.5 to 14) vs. 18 (IQR = 13 to 35)
ICU days, P = 0.008; 2.5 (IQR = 0 to 10) vs. 12 (IQR = 3 to 24)
ventilation days, P = 0.026).
Conclusions After adjustment for multiple variables, these data
provide no evidence for a survival benefit afforded by higher
dose RRT. However, more-intensive RRT was associated with a
favourable effect on ICU stay and duration of mechanical
ventilation among survivors. This result warrants further
exploration.
Trial Registration Cochrane Renal Group (CRG110600093).
AKI: acute kidney injury; APACHE: acute physiology and chronic health evaluation; CI: confidence interval; CRRT: continuous renal replacement ther-
apy; CVVH: continuous veno-venous haemofiltration; CVVHD: continuous veno-venous haemodialysis; CVVHDF: continuous veno-venous haemodi-
afiltration; ICU: intensive care unit; IRRT: intermittent renal replacement therapy; IQR: interquartile range; RIFLE: Risk-Injury-Failure-Loss-Endstage 
renal disease; RRT: renal replacement therapy; SAPS II: simplified acute physiology score; SOFA: sequential organ failure assessment.Page 1 of 14
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Acute kidney injury (AKI) requiring renal replacement therapy
(RRT) occurs in 5 to 6% of critically ill patients and is associ-
ated with high mortality and significant health resource utiliza-
tion [1-3]. Controversy exists as to what constitutes optimal
RRT in this setting. There are several modifiable factors in the
delivery of RRT which may potentially influence patient out-
come, including RRT modality (continuous or intermittent), sol-
ute removal mechanisms (convection, diffusion, adsorption or
combination), timing of initiation and dose of treatment. The
relationship between patient outcome and treatment dose was
first introduced in a landmark study where patients ran-
domised to post-dilution continuous veno-venous haemofiltra-
tion (CVVH) at a dose of 35 ml/kg/hour or above had improved
survival compared with those randomised to 20 ml/kg/hour
[4]. Since then, this issue has been explored in other studies
with conflicting results [5-9]. The Acute Dialysis Quality Initia-
tive recommends a higher dose in the absence of definitive
data, particularly in septic patients [10,11]. However, practice
surveys suggest that this threshold dose has not been widely
adopted into current intensive care units (ICU) practice
[12,13].
We performed a prospective European multicentre observa-
tional cohort study to evaluate the prescription and actual-
delivered RRT dose in ICUs and its relationship with patient
outcome, such as mortality and duration of mechanical ventila-
tion and ICU stay. Our hypothesis was that a higher RRT dose
would be associated with better patient outcomes.
Materials and methods
This study was conducted from June 2005 to December 2007
in 757 patients enrolled in 30 ICUs in eight countries. The pro-
tocol was approved by the institutional review boards of the
five Steering Committee members. Written informed consent
was obtained from patients or next of kin when required by a
centre's review board. The design of the study was published
in 2005 [14], and registered in the Cochrane Renal Group
(CRG110600093).
Study population
All incident patients aged 12 years or older treated with RRT
in the ICU were eligible for inclusion in the study. Patients with
pre-existing chronic kidney disease stage 5 were excluded
from analysis. Patients were categorised by treatment modality
(Figure 1). AKI was defined using the Risk-Injury-Failure-Loss-
End stage renal disease (RIFLE) classification [15].
Data collection
Data from enrolled patients were entered into electronic case
report forms resident on a password-protected web server
[16]. Individual centres only had access to data relevant to
their patients. Multiple data elements were collected for each
patient [14]. Periodic audits were performed to establish the
integrity of data capture and transfer into the database, as well
as data accuracy.
Figure 1
Profile of study population. Calculation of RRT dose was performed on patients who were treated exclusively on one RRT schedule (CRRT only or 
IRRT only). Forty six patients were treated with mixed RRT schedules (CRRT + CPFA, n = 10; CRRT + IRRT, n = 36; see text for explanation). AKI 
= acute kidney injury; CKD = chronic kidney disease; CPFA = coupled plasmafiltration adsorption; CRRT = continuous renal replacement therapy; 
ESRD = end-stage renal disease; ICU = intensive care unit; IRRT = intermittent renal replacement therapy.Page 2 of 14
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Although several mathematical models have been developed
to correlate the RRT dose given on different schedules (i.e.
intermittent (IRRT) and continuous (CRRT)), none of these
models have been rigorously validated in clinical practice [17-
19]. We therefore chose to express the dose of CRRT and
IRRT based on current clinical practice rather than a theoreti-
cal equivalent expression of dose [see Additional data file 1].
CVVH, continuous veno-venous haemodialysis (CVVHD), con-
tinuous veno-venous haemodiafiltration (CVVHDF) and high
volume hemofiltration (HVHF) were analysed together as
CRRT; dose was calculated using total effluent (the sum of the
dialysate and ultrafiltrate) with correction for percentage pre-
dilution, and expressed as ml/kg/hour [20]. IRRT dose was
expressed as the number of sessions per week [9]. Patients
were categorised into those receiving more-intensive (CRRT ≥
35 ml/kg/hour, IRRT ≥ 6 sessions/week) [9] or less-intensive
(CRRT < 35 ml/kg/hour, IRRT < 6 sessions/week). Distribu-
tion of CRRT and IRRT dose are shown in Figure 1 in Addi-
tional data file 2. RRT and concurrent ICU care were instituted
and prescribed at discretion of the treating physician.
End points
ICU mortality was the primary outcome. The secondary out-
comes were ICU length of stay and duration of mechanical
ventilation.
Statistical analyses
Continuous variables are expressed as mean ± standard devi-
ation or median (interquartile range) and compared between
any two groups using t-test or the Mann Whitney U test, and
among three groups using analysis of variance (general linear
models with adjustment for multiple comparisons) or the
Kruskal-Wallis test, where appropriate. Categorical variables
are expressed as proportions and compared with the Mantel-
Haenszel chi-squares test or Fisher's exact test.
For the analysis of RRT dose versus outcome, CRRT and IRRT
patients were analysed separately because of well-recognised
differences between these populations in observational stud-
ies [21,22]. Exploratory univariate analysis for several variables
was performed to identify possible risk (or protective) factors
associated with ICU mortality. Multivariable logistic regression
analysis was then conducted to test the relationship between
RRT dose and ICU mortality, adjusted for confounding factors.
Based on the results of the univariate analysis, the covariates
included in the CRRT model were sex, age (10-year incre-
ments), sequential organ failure assessment (SOFA) and
serum creatinine at CRRT initiation and CRRT downtime
(hours); for IRRT the covariates included were age (10-years
increments), sex and RIFLE class at IRRT initiation. In addition
to adjusting for significant covariates, residual confounding
and selection effects were addressed using propensity
scores. We generated a propensity score using multivariable
logistic regression with more-intensive RRT dose as the
dependent variable, as previously described [22,23]. Varia-
bles included in the propensity score were gender, weight,
SOFA score and serum creatinine at RRT initiation. We fitted
models for ICU mortality only adjusted for covariates and a
combination of covariates plus the propensity score. We
assessed for collinearity between variables using tolerance
and variance inflation factors; there was no significant colline-
arity detected. The model's goodness of fit was tested with the
Hosmer-Lemeshow statistic.
As sensitivity analyses, RRT dose was evaluated as both con-
tinuous variables and categorical variables. As continuous var-
iable for CRRT, we used the actual value or as increments of
10 ml/kg/hour; for IRRT, we used number of IRRT sessions
per week (possible range: 1 to 7). As categorical variables, we
created RRT dose categories based on the literature, as well
as standard statistical groupings (median, tertiles). Posthoc
multivariate analyses were also performed limiting the analysis
to specific subgroups of CRRT patients (septic patients, by
simplified acute physiology score (SAPS) scores, ≥ 25 hours
of CRRT). Because of the relatively small sample size of the
IRRT, subgroup analysis was not performed.
Finally, ICU survival by RRT dose categories was presented
graphically using Kaplan-Meier product limit survival plot. Two-
tailed p values less than 0.05 were considered significant. Sta-
tistical analyses were conducted using STATA 10 (StataCorp
LP, College Station, TX, USA).
Results
Enrollment and baseline characteristics
Characteristics of the participating centres are shown in Table
1 in Additional data file 2. The median enrollment period in
each study centre was 384 days. During the study period,
about 15,200 patients were admitted to participating ICUs.
Among them, 757 patients were treated with RRT sometime
during the ICU stay (Figure 1). Of the 757 enrolled patients,
we excluded patients (n = 19) who received concomitant
extracorporeal treatments (e.g. endotoxin adsorption) other
than those specified in the methods of this report, and those
with incomplete data (n = 117). The majority of incomplete
data was due to one missing datapoint needed to calculate
RRT dose on a specific day, such as percentage pre-dilution
or actual start or stop time. Complete data on pre-specified
outcomes were not available for 11 patients (1.4%).
Among the remaining 553 AKI patients, 419 received CRRT
only, 88 received IRRT only and 46 were treated with mixed
RRT schedules (IRRT, CRRT, coupled plasmafiltration adsorp-
tion). As patients in this last group crossed over from one RRT
modality to another, delivered dose could not be calculated
due to lack of clinically validated models, and they were
excluded from the analysis. Among patients treated on only
one RRT schedule (either continuous only or intermittent only),Page 3 of 14
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Table 1
Clinical characteristics of ICU patients receiving RRT
All CRRT IRRT Mixed RRT P CRRT vs IRRT P (three groups)
n (%) 471 338 (72) 87 (18) 46 (10)
Male sex (%) 67.7 66.6 70.1 71.7 0.529 0.679
Age (years) 63.6 ± 16.2 62.1 ± 16.9 68.3 ± 13 65.8 ± 14.7 0.004 0.009
Body weight (kg) 79.3 ± 19.3 79.4 ± 19.7 77.9 ± 19.6 81.4 ± 15 0.269 0.229
ICU admission
SAPS II 50 ± 18 50 ± 17 50 ± 19 51 ± 21 0.508 0.788
SOFA 10 ± 4 10 ± 3 10 ± 3 11 ± 4 0.703 0.012
Creatinine (μmol/L) 99(80 to 150) 100 (80 to 150) 106 (80 to 177) 97 (80 to 115) 0.277 0.278
Chronic kidney 
disease (%)
56.3 55.9 55.2 60.9 0.901 0.796
Diagnosis
Sepsis (%) 32.7 38.8 14.9 21.7 < 0.001 < 0.001
Post-surgical (%) 29.7 21.9 51.7 45.7 < 0.001 < 0.001
Admission department
Emergency (%) 30.4 33.4 19.5 28.3 0.012 0.040
Medicine (%) 21.0 24.0 12.6 15.2 0.022 0.041
Surgery (%) 48.6 42.6 67.8 56.5 < 0.001 < 0.001
Hospital to ICU 
admission (days)
1 (0 to 5) 1 (0 to 4) 2 (0 to 7) 1 (0 to 5) 0.042 0.146
RRT
ICU admission to start 
RRT (days)
3 (1 to 7) 2 (1 to 7) 3.5 (1 to 8.5) 3 (2 to 5) 0.884 0.700
RIFLE class at RRT 
initiation
Risk (%) 11.3 12.7 5.8 10.9 0.067 0.186
Injury (%) 28.5 27.5 31.0 30.4 0.515 0.746
Failure (%) 57.3 56.8 60.9 54.3 0.489 0.759
Non-renal 
indication (%)
2.8 3.0 2.3 2.2 0.740 0.920
SOFA at RRT initiation 11 ± 3 12 ± 3 10 ± 2 13 ± 3 < 0.001 < 0.001
Creatinine at RRT 
initiation (μmol/L) 265 (177 to 368) 274 (177 to 380) 243 (203 to 301) 194 (141 to 309) 0.319 0.031
Start to end RRT 
(days)
3 (2 to 7) 3 (2 to 6) 4 (2 to 7) 13.5 (7 to 26.5) 0.113 < 0.001
Indication for RRT 
initiation
Azotaemia 72.1 67.9 86.2 76.1 0.001 0.003
RIFLE class 64.4 64.9 60.9 67.4 0.495 0.715
Fluid overload 58.6 61.6 51.7 50.0 0.096 0.116
Oliguria 43.6 48.1 28.7 39.1 0.001 0.004
Outcome
ICU mortality (%) 47.6 54.1 22.1 44.7 < 0.001 < 0.001
Mechanical ventilation 
(days)
10 (3 to 19) 10 (4 to 19) 8 (1 to 17) 16 (11 to 38) 0.037 0.002
ICU length of stay 
(days)
14 (7 to 27) 13 (6.5 to 26) 14 (6 to 23) 25 (15 to 42) 0.769 < 0.001
CRRT = continuous renal replacement therapy; ICU = intensive care unit; IRRT = intermittent renal replacement therapy; RIFLE = Risk-Injury-
Failure-Loss-Endstage renal disease; RRT = renal replacement therapy; SAPS II = simplified acute physiology score; SOFA = sequential organ 
failure assessment.
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tice in Europe as previously reported. Out of 419 CRRT
patients, 81 patients had at least one interruption of 18 hours
or more, and then resumed CRRT [14]. The median interrup-
tion time was 49 hours (IQR = 29 to 113), predominantly due
to filter clotting, disconnection for procedures and change in
patient clinical status (e.g. CRRT not required in a window
period). As daily CRRT dose would appear artificially low in
this situation, such patients were not included in the analysis.
Eighty eight patients (18%) were treated exclusively with
IRRT. One patient had only three IRRT sessions over a span of
146 days, and was excluded from analysis (Figure 1).
Characteristics of the study population are described in Table
1. CRRT patients were younger, more likely to have sepsis,
more likely to have been admitted directly into the ICU from the
emergency room and less likely to be surgical patients. The
mean serum creatinine at RRT initiation was 265 μmol/L.
Nearly 60% of all patients were in RIFLE class Failure at RRT
initiation. A small minority of patients did not meet criteria even
for Risk, and were labelled as a non-renal indication (e.g. vol-
ume overload). Among the reasons cited to start RRT, azotae-
mia was significantly more common in the IRRT group, and
oliguria in the CRRT group. Crude ICU mortality was 54% in
the CRRT group, 22% in the IRRT group and 45% in the
mixed group.
Patient characteristics by RRT dose
CRRT
In the CRRT group, the median delivered RRT dose was 27.1
ml/kg/hour (IQR = 22.1 to 33.9). Only 75 patients (22%)
received more-intensive dose (≥ 35 ml/kg/hour), while 262
(78%) received less-intensive CRRT. In further detail, 202
(60%) received a dose between 21 and 34 ml/kg/hour, and
61 (18%) received a dose of 20 ml/kg/hour or less (Table 2).
Patients were also divided into tertiles of RRT dose (Table 2 in
Additional data file 2). Median treatment downtime, i.e. the
amount of time the CRRT was not running in a 24-hour period,
was one hour (IQR = 0 to 2). The most common causes for
CRRT interruption were clotting of the circuit (74% of epi-
sodes), vascular access problem (11%) and clinical reasons
(10%). The median prescribed CRRT dose was estimated at
34.3 ml/kg/hour (IQR = 27.3 to 42.9). Eighty seven percent of
patients used replacement fluid in various proportions of pre-
dilution (median 70%, IQR = 33 to 100). Patients receiving
CRRT of 35 ml/kg/hour or above had lower body weight,
higher admission SAPS II and SOFA scores, and a trend
towards lower serum creatinine at RRT initiation (Table 2). The
net fluid removal did not differ between the more- and less-
intensive groups: the median was 852 ml/day (IQR = 221 to
1693) in more-intensive CRRT, and 928 ml/day (IQR = 428 to
1996) in less-intensive CRRT (P = 0.22).
IRRT
In the IRRT group (Table 3), the median delivered dose was 7
sessions/week (IQR = 5 to 7). Fifty six patients (64%)
received more-intensive IRRT, while 31 (36%) were treated
with the less-intensive dose. In further detail, 51 patients
(59%) received daily dialysis, while five (6%) had 6 sessions/
week, 10 (11%) had five sessions/week and 21 (24%)
received alternate day dialysis (3 to 4 sessions/week). The
median dialysis duration was 5.5 (IQR = 4 to 9) hours. The
median prescribed Kt/V per session was estimated at 1.2
(IQR = 0.8 to 1.9). More-intensive IRRT patients were more
likely to be septic compared with the less-intensive group
(Table 3). The net fluid removal was similar between the more-
and less-intensive groups: the median was 780 ml/day (IQR =
410 to 1115) in more-intensive IRRT, and 829 ml/day (IQR =
485 to 1103) in less-intensive IRRT (P = 0.68).
Outcomes
CRRT
On univariate analysis, age, SAPS II, SOFA score and serum
creatinine on admission, SOFA score and serum creatinine on
RRT initiation, and RRT duration were significantly associated
with ICU mortality. On multivariate analysis, CRRT dose was
not associated with ICU mortality (Table 4). Further adjust-
ment for the propensity score did not significantly alter this
result (adjusted odds ratio (OR) = 1.40, 95% confidence
interval (CI) = 0.74 to 2.65). Kaplan Meier curves are shown
in Figures 2 and 3 in Additional data file 2. Results were similar
whether CRRT dose was expressed as a continuous or cate-
gorical variable (Table 5). Additional post-hoc sensitivity anal-
yses were performed (Table 6). Results were similar in
patients with and without sepsis. We also performed sub-
group analysis on the following patient subgroups: those with
intermediate severity of illness (SAPS II scores from 45 to 60),
and those who had a minimum exposure of 25 hours for CRRT
therapy.
Similarly, there was no relation between CRRT dose and ICU
mortality in these two subgroups. Patients who received more-
intensive CRRT overall had shorter duration of mechanical
ventilation and ICU stay (Table 7). Among survivors, there was
a trend towards shorter ICU stay (P = 0.063), while duration
of mechanical ventilation was significantly less (P = 0.031).
Similar to the overall group, survivors in the more-intensive
CRRT group had significantly lower body weight and shorter
ICU stay prior to CRRT initiation (2 days, IQR = 1 to 3; vs. less-
intensive 3 days, IQR = 2 to 7.5; P = 0.002), compared with
the less-intensive CRRT group. Otherwise, the survivors in the
two groups had similar baseline characteristics.
IRRT
None of the variables examined, including IRRT dose, were
significantly associated with ICU mortality on univariate and
multivariate analysis (Table 8). This was seen whether IRRT
dose was expressed as a dichotomous variable (more- vs.Page 5 of 14
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Table 2
Clinical characteristics of CRRT patients by CRRT dose (≤ 20, 21 to 34, and ≥ 35 ml/kg/hour)
Less-intensive (< 35 ml/kg/hour) More-intensive
≤ 20 ml/kg/hour 21 to 34 ml/kg/hour ≥ 35 ml/kg/hour P
n (%) 61 (18) 202 (60) 75 (22)
Male sex (%) 73.8 67.8 58.1 0.139
Age (years) 59.05 ± 19.0 63.48 ± 15.9 61.01 ± 17.4 0.226
Body weight (kg) 91.66 ± 24.4 79.70 ± 18.0 68.81 ± 12.8 < 0.001
ICU admission
SAPS II 46 ± 19 51 ± 17 52 ± 16 0.030
SOFA 9 ± 4 10 ± 3 11 ± 4 0.030
Creatinine (μmol/L) 106 (88 to 150) 97 (80 to 150) 106 (80 to 150) 0.597
Chronic kidney disease (%) 47.5 58.9 55.4 0.290
Diagnosis
Sepsis (%) 31.2 40.1 40.5 0.419
Post-surgical (%) 24.6 21.3 21.6 0.859
Admission department
Emergency (%) 36.1 35.2 25.7 0.292
Medicine (%) 16.4 23.3 32.4 0.087
Surgery (%) 47.5 41.6 41.9 0.702
Hospital to ICU admission (days) 0.5 (0 to 4) 1 (0 to 4) 1 (0 to 3) 0.654
RRT
ICU admission to RRT (days) 2.5 (2 to 8) 3 (2 to 7) 2 (1 to 3) 0.005
RIFLE class at RRT initiation
Risk (%) 19.7 9.9 13.5 0.123
Injury (%) 18.0 27.7 35.1 0.086
Failure (%) 55.7 59.9 50.0 0.331
Non-renal indication (%) 6.6 2.5 1.4 0.168
SOFA at RRT initiation 11 ± 3 12 ± 3 12 ± 3 0.068
Creatinine at RRT initiation (μmol/L) 283 (177 to 389) 283 (194 to 415) 221 (168 to 327) 0.052
CRRT dose (ml/kg/hour) 15.4 ± 4.2 26.9 ± 4.0 44.8 ± 9.4 < 0.001
Start to end RRT (days) 3 (2 to 6) 4 (2 to 8) 2 (1 to 3) < 0.001
Indication for RRT initiation
Azotaemia 65.0 70.0 63.9 0.559
RIFLE class 56.7 70.0 56.9 0.048
Fluid overload 61.7 62.5 59.7 0.917
Oliguria 49.5 41.7 48.6 0.562
Outcome
ICU mortality (%) 50.8 53.0 60.8 0.426
Mechanical ventilation (days) 13 (3 to 23) 12 (5 to 20) 5 (2.5 to 13) < 0.001
ICU length of stay (days) 17 (7.5 to 29) 15 (9 to 27) 8 (4 to 18) < 0.001
CRRT = continuous renal replacement therapy; ICU = intensive care unit; RIFLE = Risk-Injury-Failure-Loss-Endstage renal disease; RRT = renal 
replacement therapy; SAPS II = simplified acute physiology score; SOFA = sequential organ failure assessment.
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Table 3
Clinical characteristics of IRRT patients by IRRT dose (< 6 and ≥ 6 sessions per week)
Frequency < 6 days/week Frequency ≥ 6 days/week P
n (%) 31 (36) 56 (64)
Male sex (%) 71.0 69.6 0.897
Age (years) 69.13 ± 11.7 67.84 ± 13.7 0.873
Body weight (kg) 79.52 ± 15.7 76.99 ± 21.6 0.246
ICU admission
SAPS II 49 ± 15 50 ± 20 0.958
SOFA 10 ± 3 9 ± 4 0.689
Creatinine (μmol/L) 106 (80 to 186) 106 (80 to 177) 0.822
Chronic kidney disease (%) 54.8 55.4 0.963
Diagnosis
Sepsis (%) 3.2 21.4 0.023
Post-surgical (%) 64.5 44.6 0.076
Admission department
Emergency (%) 12.9 23.2 0.245
Medicine (%) 12.9 12.5 0.957
Surgery (%) 74.2 64.3 0.343
Hospital to ICU admission (days) 3 (0 to 8) 1 (0 to 6) 0.322
RRT
ICU admission to RRT (days) 5 (1 to 11) 3 (1 to 7) 0.351
RIFLE class at RRT initiation
Risk (%) 6.5 5.4 0.834
Injury (%) 41.9 25.0 0.102
Failure (%) 51.6 66.1 0.186
Non renal indication (%) 0.0 3.6 0.287
SOFA at RRT initiation 10 ± 2 10 ± 2 0.941
Creatinine at RRT initiation (μmol/L) 247 (199 to 296) 234 (212 to 301) 0.880
Number of sessions per week 4.5 ± 0.8 6.9 ± 0.2 < 0.001
Start to end RRT (days) 6 (5 to 12) 3 (1 to 5) < 0.001
Indication for RRT initiation
Azotaemia 96.8 80.4 0.033
RIFLE class 58.1 62.5 0.685
Fluid overload 41.9 57.1 0.174
Oliguria 22.6 32.1 0.345
Outcome
ICU mortality (%) 19.4 23.6 0.646
Mechanical ventilation (days) 14 (5 to 21) 6 (0 to 14) 0.030
ICU length of stay (days) 18 (13 to 31) 9.5 (6 to 18) 0.023
ICU = intensive care unit; IRRT = intermittent renal replacement therapy; RIFLE = Risk-Injury-Failure-Loss-Endstage renal disease; RRT = renal 
replacement therapy; SAPS II = simplified acute physiology score; SOFA = sequential organ failure assessment.
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sions per week (unadjusted OR = 1.11, 95% CI = 0.74 to
1.69). Because of the relatively small sample size, no further
sensitivity analysis was attempted. Patients who received
more-intensive IRRT had shorter duration of mechanical venti-
lation and ICU stay, particularly among survivors (Table 7).
Survivors in the more-intensive IRRT group were more likely to
have sepsis (23% vs. less-intensive 0%, P = 0.008), com-
pared with the less-intensive IRRT group. Otherwise, the sur-
vivors in the two groups had similar baseline characteristics.
Discussion
We conducted a European multicentre observational study to
describe clinical outcomes associated with RRT dose in criti-
cally ill patients with AKI. The key findings of this study are the
following. First, despite a prescribed CRRT dose approximat-
ing 35 ml/kg/hour, the recommended 'minimum' for critically ill
AKI patients according to expert opinion [10,24], the delivered
CRRT dose was markedly lower than this value. Second, it
appears that alternate day IRRT for critically ill patients is
uncommon in the participating centres. Third, after adjustment
for multiple variables, we did not observe a beneficial effect of
more-intensive RRT dose on ICU survival. Fourth, ICU stay and
ventilation days were shorter in the more-intensive RRT
groups.
Our findings on mortality are congruent with an international
observational study [25] and two recent randomised clinical
trials on standard versus higher-dose CVVHDF including the
large multicentre Veterans Affairs/National Institute of Health
(VA/NIH) trial in the US [8,9]. There are conflicting results on
the effect of RRT dose on patient outcome. Two earlier single-
centre randomised clinical trials showed a beneficial effect of
an intensive CRRT dose when compared with a less-intensive
dose in both CVVH (≥ 35 ml/kg/hour versus ≤ 20 ml/kg/hour)
[4] and CVVHDF (≥ 42 ml/kg/hour versus ≤ 25 ml/kg/hour)
[7]. In contrast, Bouman and colleagues did not detect any dif-
ference in outcome between ultrafiltration rates of 3 to 4 l/hour
and 1 to 1.5 l/hour; however, this study suffered from lack of
power and an unexpectedly high ICU survival rate among
enrolled subjects [5]. Interestingly, in contrast to other studies
[5,7-9], we observed a positive effect of more-intensive RRT
dose on ICU stay and duration of mechanical ventilation.
Our study has several notable features. It is the first large
observational study specifically oriented towards RRT dose
involving multiple ICUs which are a mix of academic and non-
academic centres. As such, it is likely to be more reflective of
actual clinical practice and a broad patient population. Indeed,
in the CRRT group, the prevalence of sepsis was 39% and the
overall mortality was 54%. This is similar to that described in
the literature [3,6,7,9,22].
Second, it focused on delivered, rather than prescribed, RRT
dose. This is not a minor point, as many factors contribute to
delivering a RRT dose lower than prescribed, and it is the
delivered dose which the patient 'sees' and which is likely to
affect the clinical outcome. A prior observational study
reported only on prescribed, but not the delivered, CRRT dose
[25]. Furthermore, ours is the first dose study in which correc-
tion for percentage predilution was performed in the calcula-
tion of CRRT dose, resulting in a more accurate estimate. It
has been shown that delivered dialysis dose is generally lower
than prescribed, ranging from 68 to 89% of prescribed
[7,8,26,27].
Third, we specifically collected information on treatment
'downtime', which is considered an important factor affecting
delivered RRT dose.
Fourth, it is also one of only two studies to look at a continuum
of RRT dose so far [25]. Of note, the majority of patients
received a CRRT dose which was in between the 'standard/
low dose' and the 'high dose' arms evaluated in randomised
Table 4
Unadjusted and covariate adjusted analysis for ICU mortality in CRRT patients
CRRT Unadjusted analysis Covariate adjusted analysis
OR 95% CI P OR 95% CI P
Male sex 1.47 0.91 to 2.37 0.097 1.86 1.11 to 3.12 0.019
Age (10-year increments) 1.34 1.17 to 1.52 < 0.001 1.42 1.22 to 1.64 < 0.001
SOFA at RRT initiation 1.18 1.09 to 1.28 < 0.001 1.20 1.10 to 1.30 < 0.001
Creatinine at RRT initiation (μmol/L) 0.85 0.76 to 0.95 0.005 0.79 0.69 to 0.90 0.001
Downtime 0.90 0.80 to 1.01 0.081 0.95 0.83 to 1.07 0.386
More-intensive (≥ 35 ml/kg/hour) 1.41 0.83 to 2.38 0.204 1.21 0.66 to 2.21 0.537
CI = confidence interval; CRRT = continuous renal replacement therapy; ICU = intensive care unit; OR = odds ratio; RRT = renal replacement 
therapy; SOFA = sequential organ failure assessment.Page 8 of 14
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'intermediate' zone served to dilute the true clinical effect of
RRT dose remains unclear. It has been suggested that only
major changes in the application of dose can be reasonably
expected to have a discernible clinical effect [28]. For exam-
ple, the difference between a delivered CRRT dose of 30 and
35 ml/kg/hour may be too subtle, or could be criticised for
being within a calculation error. However, we performed a vari-
ety of analyses which included expressing dose in increments
of 10 ml/kg/hour (arbitrarily considered a 'significant' incre-
ment), or as categories based on cut-offs from the literature or
on statistical spread (e.g. tertiles, median), and failed to find a
significant effect on ICU mortality (Table 5). It is also possible
that therapy in the first 24 to 48 hours is more crucial with
respect to patient outcome. We therefore performed a post-
hoc sensitivity analysis looking at CRRT dose during these
periods (Table 5), and this did not significantly alter the results.
It has been suggested that septic patients may be a specific
population which could benefit from higher RRT dose [4,11].
In our post-hoc analysis, the effect of RRT dose on mortality
was similar in both septic and non-septic patients (Table 6). It
is also possible that more-intensive RRT only benefits patients
with an intermediate severity of illness, as suggested by
Paganini and colleagues [29]. We performed two sensitivity
analyses to address this. First, we limited the analysis only to
patients with SAPS scores between 45 and 60, in whom the
predicted mortality ranges from 35 to 60%. In five studies eval-
uating the effects of CRRT dose, mean acute physiology and
chronic health evaluation (APACHE) II scores ranged from 22
to 26, giving predicted mortality rates of 42 to 57% in this
Table 5
Sensitivity analysis for ICU mortality in CRRT patients
CRRT dose expressed as Unadjusted OR with 95% CI P value Adjusted OR with 95% CI P value
Raw value (ml/kg/hour) 1.00 (0.98 to 1.02) 0.827 0.99 (0.97 to 1.02) 0.583
Increment of 10 ml/kg/hour 1.05 (0.87 to 1.26) 0.638 0.98 (0.79 to 1.23) 0.879
Literature cut-offs
≤ 20 ml/kg/hour (ref.) 1.00 1.00
21 to 34 ml/kg/hour 1.09 (0.61 to 1.93) 0.768 0.79 (0.40 to 1.55) 0.492
≥ 35 ml/kg/hour 1.50 (0.76 to 2.98) 0.245 1.00 (0.45 to 2.24) 0.995
Less-intensive (< 35 ml/kg/hour) (ref.) 1.00 1.00
More-intensive (≥ 35 ml/kg/hour) 1.41 (0.83 to 2.38) 0.204 1.21 (0.66 to 2.21) 0.537
≤ 20 ml/kg/hour (ref.)
> 20 ml/kg/hour 1.19 (0.68 to 2.07) 0.546 0.84 (0.43 to 1.61) 0.595
Tertiles
1st tertile (≤ 23.5 ml/kg/hour) (ref.) 1.00 1.00
2nd tertile (23.6 to 30.9 ml/kg/hour) 0.71 (0.42 to 1.20) 0.206 0.67 (0.37 to 1.23) 0.196
3rd tertile (≥ 31 ml/kg/hour) 1.32 (0.78 to 2.24) 0.306 1.11 (0.60 to 2.06) 0.734
1st+2nd tertiles (ref.)
3rd tertile 1.56 (0.98 to 2.48) 0.058 1.36 (0.79 to 2.32) 0.268
Median
< Median (ref.) 1.00 1.00
≥ Median (≥ 27.1 ml/kg/hour) 0.99 (0.64 to 1.51) 0.945 0.82 (0.49 to 1.35) 0.433
CRRT dose in first 24 hours
Less-intensive (< 35 ml/kg/hour) (ref.) 1.00 1.00
More-intensive (≥ 35 ml/kg/hour) 1.02 (0.65 to 1.62) 0.918 0.96 (0.57 to 1.60) 0.866
CRRT dose in first 48 hours
Less-intensive (< 35 ml/kg/hour) (ref.) 1.00 1.00
More-intensive (≥ 35 ml/kg/hour) 1.08 (0.68 to 1.74) 0.737 1.03 (0.60 to 1.76) 0.915
CI = confidence interval; CRRT = continuous renal replacement therapy; ICU = intensive care unit; OR = odds ratio.Page 9 of 14
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Second, patients may have a very short duration of RRT for
various reasons. For example, they may be gravely ill and die
shortly after RRT initiation. Alternatively, they may be less ill
and have rapid recovery of renal function allowing early with-
drawal of RRT. Therefore, we performed a secondary analysis
looking only at patients who had at least 25 hours of RRT. This
was adapted from the definition of an 'adequate trial of ther-
apy' in a randomised trial comparing CRRT and IRRT [30]. The
results remained qualitatively unchanged.
Table 6
Subgroup analysis for ICU mortality in CRRT patients
More-intensive vs less-intensive CRRT dose* Unadjusted OR* with 95% CI P value Adjusted OR* with 95% CI P value
Patient subgroups
Sepsis 1.64 (0.70 to 3.85) 0.259 1.91 (0.71 to 5.13) 0.198
Non sepsis 1.27 (0.65 to 2.48) 0.488 0.95 (0.43 to 2.10) 0.896
SAPS II 45 to 60 1.03 (0.44 to 2.40) 0.945 0.67 (0.24 to 1.81) 0.428
SAPS II < 45 or > 60 1.69 (0.85 to 3.31) 0.129 1.76 (0.80 to 3.86) 0.159
≥ 25 hours of CRRT 1.06 (0.55 to 2.01) 0.870 1.07 (0.51 to 2.28) 0.855
< 25 hours of CRRT 1.72 (0.61 to 4.86) 0.303 1.12 (0.34 to 3.73) 0.854
*OR refers to more-intensive CRRT with respect to the reference group less-intensive CRRT.
CI = confidence interval; CRRT = continuous renal replacement therapy; ICU = intensive care unit; OR = odds ratio; SAPS II = simplified acute 
physiology score.
Table 7
ICU length of stay and ventilation days by RRT dose
Total CRRT
< 35 ml/kg/hour ≥ 35 ml/kg/hour P
Length of ICU stay (days) 13 (6.5 to 26) 15 (9 to 28) 8 (4 to 18) < 0.001
Patients who survived 19 (11 to 32) 19.5 (12 to 33.5) 15 (8 to 26) 0.063
Patients who died 10 (4 to 19) 12 (6 to 20) 4.5 (3 to 9.5) < 0.001
Duration of MV (days) 10 (4 to 19) 12 (5 to 21) 5 (2.5 to 13) < 0.001
Patients who survived 14 (4.5 to 22) 14 (5 to 24) 7 (4 to 17) 0.031
Patients who died 8.5 (3 to 17) 10 (5 to 18) 4 (2 to 9.5) < 0.001
IRRT
Total Frequency < 6 sessions/week Frequency ≥ 6 sessions/week P
Length of ICU stay (days) 14 (6.5 to 23) 18 (15 to 31) 9.5 (6 to 18) 0.023
Patients who survived 11 (6 to 20) 18 (13 to 35) 8 (5.5 to 14) 0.008
Patients who died 17 (12 to 23) 18 (17 to 23) 15 (12 to 22) 0.597
Duration of MV (days) 8 (1 to 17) 14 (5 to 21) 6 (0 to 14) 0.030
Patients who survived 5 (0 to 13) 12 (3 to 24) 2.5 (0 to 10) 0.026
Patients who died 17 (11 to 21) 18 (17 to 21) 14 (8 to 18) 0.252
Data shown as median (interquartile range).
CRRT = continuous renal replacement therapy; ICU = intensive care unit; IRRT = intermittent renal replacement therapy; MV = mechanical 
ventilation.Page 10 of 14
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delivery of RRT dose in current clinical practice. There is a gap
between prescribed and delivered CRRT dose, as has been
shown by others [7,8,26,27]. Treatment downtime is a known
contributing factor. In contrast to earlier studies, however, we
also considered the effect of percentage pre-dilution in calcu-
lating the delivered dose. We hypothesise that lack of atten-
tion to this when prescribing CRRT may play a heretofore
unrecognised role in under-delivery of dose. As modern
machines are able to provide replacement fluid in variable pro-
portions of pre/post-dilution, it is important to keep this in
mind. We also observed that CRRT patients receiving more-
intensive dose had significantly lower body weights. This may
represent indiscriminate 'by the litre' prescription, rather than
'individualised' prescription based on body weight [13]. It is
also possible that it is simply more difficult to provide higher
doses in larger patients with currently available technology.
Perhaps the greatest concern arising from the observed gap
between prescription and delivery is the potential downstream
effect of prescribing 20 ml/kg/hour to patients. There would
be a real risk of effectively underdialysing patients [31].
We acknowledge certain limitations in this study. As with all
observational studies, ours may have suffered from 'selection
by prognosis' [32]. Indeed, it is quite plausible that, based on
existing literature, the treating intensivist or nephrologist would
prescribe a higher RRT dose to a sicker patient, who a priori
has a higher predicted mortality. Although we adjusted for
potential confounders, including propensity score analysis
(Table 3 in Additional data file 2), this may still be insufficient
because it is not possible to adjust for confounders that are
neither measured nor known. We also chose to exclude a
number of patients from the analysis, which may have resulted
in some selection bias. It was not possible to analyse patients
who crossed over between modalities because there is no sin-
gle equivalent expression of dose clinically validated for both
CRRT and IRRT. However, when we compared the analysed
group to the overall population, they were similar in terms of
demographics, general severity of illness and co-morbidities.
Therefore, if selection bias was present, its effect is likely to be
minimal. For IRRT patients, we were unable to correlate out-
come with the measured Kt/V, as the necessary laboratory
parameters for the calculation were not collected as part of
routine practice. This is consistent with the findings of the VA/
NIH group in their pre-trial survey that assessment of the deliv-
ered dose of IRRT was performed infrequently in clinical prac-
tice [13]. Nevertheless, we believe we have a reasonable
estimate of prescribed IRRT dose based on the operational
parameters collected, with a median prescribed Kt/V of 1.2.
Although we found an inverse relationship between RRT dose
and duration of mechanical ventilation, as well as with ICU
stay, we acknowledge that there were no standard criteria for
extubation or ICU discharge in this observational study. Fur-
thermore, we only looked at short-term outcomes. Future stud-
ies should attempt to better understand the long-term effects
of RRT dose. Lastly, this was a voluntary survey conducted in
predominantly CRRT-oriented centres. As such, it may not be
possible to generalise the results to other medical centres. It
is noteworthy, however, that despite being CRRT-oriented
centres, the delivered CRRT dose, although higher than
reported in prior studies [26,28], still fell short of the mark. This
begs the question as to whether a dose of 35 ml/kg/hour or
45 ml/kg/hour [4,11], as suggested for septic patients, is rou-
tinely achievable in the real world.
Nevertheless, our findings of reduced ICU stay and mechani-
cal ventilation days with more-intensive RRT may potentially
have a large impact on health resource utilisation, if confirmed
by future studies. For example, the average total cost per ICU
day has been estimated at €1200 in a sample of European
countries [33]. A possible implication would be potential sav-
ings of €8000 to 10,200 per ICU admission with more-inten-
Table 8
Unadjusted and covariate adjusted analysis for ICU mortality in IRRT patients
IRRT Unadjusted analysis Covariate adjusted analysis
OR 95% CI P OR 95% CI P
Male sex 1.28 0.37 to 5.12 0.674 1.38 0.42 to 4.58 0.598
Age (10-year increments) 1.31 0.85 to 2.01 0.216 1.29 0.83 to 2.02 0.260
RIFLE class
Risk (%) 2.51 0.19 to 23.49 0.320 1.00
Injury (%) 2.45 0.74 to 7.92 0.089 1.29 0.2 to 8.33 0.790
Failure (%) 0.38 0.12 to 1.22 0.064 0.46 0.07 to 2.88 0.408
More-intensive (≥ 6 sessions/week) 1.29 0.43 to 3.82 0.646 1.50 0.48 to 4.67 0.482
CI = confidence interval; ICU = intensive care unit; IRRT = intermittent renal replacement therapy; OR = odds ratio; RIFLE = Risk-Injury-Failure-
Loss-Endstage renal disease.Page 11 of 14
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no significant difference in duration of mechanical ventilation
between lower and higher CRRT dose groups [5,7]; however,
this issue was not specifically addressed by others [4,6,8,9].
This study highlights that the concept of RRT dose or ade-
quacy is more complex than previously thought. This adds fuel
to the debate on the optimal RRT dose for critically ill patients
with AKI. Clearly there are other dimensions to RRT adequacy
other than removal of various solutes, whether expressed as
Kt/V, ml/kg/hour or number of RRT sessions per week. These
include prophylactic volume control, as well as acid-base and
tonicity control, among others. Furthermore, recognising that
critical illness is not a static condition, a 'dynamic approach' to
RRT dose, rather than fixed dose, may be more appropriate in
this setting [34]. This hypothesis is worthy of exploration in
future studies. In addition, it is likely that there are multifaceted
interactions between RRT dose and other factors (timing of
RRT, modality, patient characteristics, etc.) which influence
outcome.
Conclusions
We conducted a prospective European multicentre cohort
study of AKI patients treated with RRT. This study provides
insight in to how RRT is currently practiced in the ICU. We
observed that the median CRRT dose is lower than 35 ml/kg/
hour and only 22% of patients received this or a higher dose.
In contrast, 60% of IRRT patients were treated daily. We eval-
uated the association between actual delivered RRT dose and
clinical outcomes. The data provide no evidence for a survival
benefit afforded by more-intensive RRT. However, higher RRT
dose appeared to be associated with shorter ICU stay and
duration of mechanical ventilation. In conclusion, within the
confines of the dose range examined, there was no effect on
survival while effects on non-mortality endpoints should be
examined by further study.
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